Scientists attack cancer before it strikes: early treatment trial aims to stop myeloma in its tracks
NCT ID NCT04933539
Summary
This study tests whether treating people with high-risk smoldering multiple myeloma—a pre-cancer condition—with a three-drug combination can prevent or delay progression to active cancer. Fourteen participants receive injections and infusions of daratumumab, carfilzomib, and dexamethasone for 8-12 months, followed by maintenance therapy. The main goal is to see if this early treatment can eliminate detectable cancer cells and prevent organ damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.